72 unknown. 72 Phase 1, 30 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 72 | Unknown 72 |
| Phase 2 | 30 | Unknown 30 |
Follow Urologic Neoplasms: new trials by email Literature Review of Urologic Neoplasms trials Research Report on Urologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer Recombinant oncolytic adenovirus injection solution of VT-101 - Non-muscle Invasive Bladder Cancer | Phase 1 | Unknown | The Affiliated Hospital of Xuzhou Medical University | 16 | 2024-09-18 | 2024-10-09 |
| Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC) 9MW2821 - Bladder Cancer | Phase 1 | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 30 | 2024-04-22 | 2024-08-13 |
| Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors TT-00420 + Toripalimab - Clear Cell Renal Carcinoma, Urothelial Carcinoma | Phase 1 / Phase 2 | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 42 | 2024-02-01 | 2024-01-24 |
| A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors CD70 CAR-T cells - Renal Cell Carcinoma, Ovarian Cancer | Phase 1 | Unknown | Chongqing Precision Biotech Co., Ltd | 48 | 2023-11-30 | 2023-11-08 |
| A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma HS-10516 - Renal Cell Carcinoma | Phase 1 | Unknown | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 190 | 2023-09-25 | 2023-09-26 |
| Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients Herpes virus T3011 injection - Bladder Cancer | Phase 1 | Unknown | Fudan University | 20 | 2023-09-21 | 2024-05-23 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers APL-1202 and APL-1501 (Single ascending dose), APL-1202 and APL-1501 (Multiple Ascending dose) - Bladder Cancer | Phase 1 | Unknown | Jiangsu Yahong Meditech Co., Ltd aka Asieris | 48 | 2023-09-09 | 2023-09-13 |
| Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic Neoplasms Anti-CD70 CAR-T cells - CD70-positive Advanced Urologic Neoplasms | Phase 1 | Unknown | Changhai Hospital | 60 | 2023-07-31 | 2023-08-14 |
| CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells - Renal Cell Carcinoma | Phase 1 | Unknown | Fudan University | 9 | 2023-07-17 | 2023-12-27 |
| A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors RC198 Injection - Melanoma, Urothelial Carcinoma | Phase 1 | Unknown | RemeGen Co., Ltd. | 48 | 2023-06-05 | 2024-08-16 |
| The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 Intravenous injection of P-IL-2, P-IL-2 plus Anti-PD-1 Monoclonal Antibody - Esophagus Cancer, Bladder Cancer | Phase 1 | Unknown | Zhejiang University | 10 | 2023-05-23 | 2024-02-13 |
| Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma Sodium Pentaborate - Renal Cell Carcinoma | Phase 1 / Phase 2 | Unknown | Tabriz University of Medical Sciences | 30 | 2023-05-22 | 2023-04-04 |
| A Study of BPI-452080 in Subjects With Solid Tumors BPI-452080 - Solid Tumor, Renal Cell Carcinoma | Phase 1 | Unknown | Betta Pharmaceuticals Co., Ltd. | 87 | 2023-04-28 | 2023-05-06 |
| Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ], Tiragolumab, Stereotactic body radiation therapy (SBRT) - Metastatic Non Small Cell Lung Cancer, Metastatic Bladder Cancer | Phase 1 | Unknown | Centre Georges Francois Leclerc | 92 | 2022-12-05 | 2023-10-17 |
| A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T CD70 CAR-T cells - Metastatic Tumor, Advanced Solid Tumor | Phase 1 | Unknown | Chongqing Precision Biotech Co., Ltd | 48 | 2022-07-17 | 2023-08-18 |
| OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer OH2 injection - Non-muscle-invasive Bladder Cancer | Phase 1 / Phase 2 | Unknown | Binhui Biopharmaceutical Co., Ltd. | 30 | 2022-07-11 | 2024-08-12 |
| Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors NGM438, Pembrolizumab (KEYTRUDA ®) - Pancreatic Cancer, Breast Cancer | Phase 1 | Unknown | NGM Biopharmaceuticals, Inc | 71 | 2022-05-11 | 2024-04-01 |
| A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 BMC128, Nivolumab - Non-small Cell Lung Cancer, Melanoma | Phase 1 | Unknown | Biomica Ltd. | 11 | 2022-05-01 | 2024-05-07 |
| Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells cytokine-induced killer cells, Standard treatment according to the Clinical protocols - Bladder Cancer, Renal Cancer | Phase 1 / Phase 2 | Unknown | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 20 | 2022-03-01 | 2022-01-14 |
| Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration - Carcinoma, Melanoma | Phase 1 | Unknown | Sichuan University | 60 | 2022-03-01 | 2022-02-11 |
Showing 20 of 72. Sign in to see all of them.
Carcinoma, Renal Cell (40) · Urinary Bladder Neoplasms (26) · Melanoma (14) · Carcinoma, Non-Small-Cell Lung (13) · Ovarian Neoplasms (13) · Colorectal Neoplasms (12) · Breast Neoplasms (11) · Kidney Neoplasms (9) · Lung Neoplasms (9) · Stomach Neoplasms (8) · Carcinoma, Hepatocellular (7) · Neoplasm Metastasis (7) · Neoplasms (7) · Esophageal Neoplasms (6) · Head and Neck Neoplasms (6)
Female Urogenital Diseases (72) · Female Urogenital Diseases and Pregnancy Complications (72) · Male Urogenital Diseases (72) · Urogenital Diseases (72) · Urologic Diseases (72) · Neoplasms by Site (71) · Urogenital Neoplasms (71) · Neoplasms (65) · Neoplasms by Histologic Type (57) · Neoplasms, Glandular and Epithelial (52) · Carcinoma (51) · Kidney Diseases (47) · Adenocarcinoma (42) · Kidney Neoplasms (38)
Cyclophosphamide (4) · Sunitinib (4) · pembrolizumab (4) · Nivolumab (3) · Bevacizumab (2) · Electroporation (2) · atezolizumab (2) · fludarabine (2) · AQ4N (1) · Biological Factors (1) · Bortezomib (1) · Capecitabine (1) · Clinical Trials, Phase II as Topic (1) · Drug Delivery Systems (1) · Drug Therapy (1)
Chongqing Precision Biotech Co., Ltd (4) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Biocad (2) · Fudan University (2) · NGM Biopharmaceuticals, Inc (2) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (2) · Affiliated Hospital to Academy of Military Medical Sciences (1) · Alliancells-PuRui Biocience Co., Ltd. (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Betta Pharmaceuticals Co., Ltd. (1) · Binhui Biopharmaceutical Co., Ltd. (1) · Biomica Ltd. (1) · Campania Younger Oncologists Association (1) · Carisma Therapeutics Inc (1) · Cell Genesys (1)
China (27) · United States (15) · Australia (3) · Netherlands (3) · United Kingdom (3) · Canada (2) · France (2) · Israel (2) · Russia (2) · South Korea (2) · Belarus (1) · Czechia (1) · Denmark (1) · Germany (1) · Iran (1)
Jianfeng Bi, M.D (2) · Adriaan D. Bins, MD PhD (1) · Alan I So, MD, FRCSC (1) · Alexander Prokhorov, Dr (1) · Andrei Hancharou (1) · Arnulf Stenzl, Prof. (1) · Daniel Castellano, MD (1) · David Quinn, MD, PhD (1) · Deborah L. Ornstein, MD (1) · Dingwei Ye (1) · Dingwei Ye, Doctor (1) · Dingwei Ye, Ph.D (1) · Dr Jonathan Krell (1)
PMID 18391430, PMID 21277078, PMID 22045104, PMID 22461641, PMID 23088985, PMID 23747347, PMID 24668644, PMID 24720900, PMID 25747273, PMID 25886058, PMID 25902855, PMID 26014293, PMID 26228759, PMID 26871284, PMID 28712033, PMID 28755959, PMID 28886381, PMID 28981385, PMID 32615118, PMID 33924556, PMID 34103518, PMID 34965951, PMID 34998048, PMID 35193932, PMID 36212980, PMID 36441083, PMID 37104017, PMID 37946136, PMID 38172595, PMID 38553868, PMID 39035212, PMID 39069239, PMID 39726590, PMID 39920391, PMID 40204996, PMID 40579407, PMID 42337683
2016 (2), 2015 (1), 2018 (1), 2019 (1), M01RR000030 (1)